Health Care › Pharmaceutical Preparations
PRPH Stock Price Correlated With ProPhase Labs Financials
External Links ⌄
Income Statement
Cash Flow
Balance Sheet
PRPH Income Statement
Enable JavaScript and reload
Revenue, Net:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
PRPH Cash Flow
Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:
PRPH Balance Sheet
Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:
COMPANY PROFILE
Note
1 – Organization and Business
ProPhase
Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a diversified
company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. We provide traditional
CLIA molecular laboratory services, including SARS-CoV-2 (“COVID-19”) testing and seek to leverage our Clinical Laboratory
Improvement Amendments (“CLIA”) accredited laboratory services to provide whole genome sequencing and research direct to
consumers, while building a genomics data base to be used for further research. In addition, we have deep experience with over-the-
counter (“OTC”) consumer healthcare products and dietary supplements. We currently conduct our operations through two operating
segments: diagnostic services and consumer products. Until late Fiscal 2020, we were engaged primarily in the research, development,
manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. However,
commencing in December 2020, we also began offering COVID-19 and other Respiratory Pathogen Panel (RPP) molecular tests through our new
diagnostic services business, and in August 2021 we began offering personal genomics products and services.
Our
wholly owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers
a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain
reaction (“PCR”) testing for COVID-19. Critical to COVID-19 testing, we provide fast turnaround times for results. We also
offer rapid antigen and antibody/immunity testing for COVID-19. On October 23, 2020, we acquired Confucius Plaza Medical Laboratory Corp.
(“CPM”), which included a non-operating but certified 4,000 square foot CLIA accredited laboratory located
in Old Bridge, New Jersey (see Note 3, Business Acquisitions). In December 2020, we expanded our diagnostic service business with the
build out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in January
2021.
On
August 10, 2021, we acquired Nebula Genomics, Inc. (“Nebula”), a privately owned personal genomics company (“Nebula”),
through our new wholly owned subsidiary, ProPhase Precision Medicine, Inc. (“ProPhase Precision”). See Note 3, Business Acquisitions.
ProPhase Precision focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes
and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict
disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.
Our
wholly owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label
developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.
1 – Organization and Business
ProPhase
Labs, Inc. (“ProPhase”, “we”, “us”, “our” or the “Company”) is a diversified
company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. We provide traditional
CLIA molecular laboratory services, including SARS-CoV-2 (“COVID-19”) testing and seek to leverage our Clinical Laboratory
Improvement Amendments (“CLIA”) accredited laboratory services to provide whole genome sequencing and research direct to
consumers, while building a genomics data base to be used for further research. In addition, we have deep experience with over-the-
counter (“OTC”) consumer healthcare products and dietary supplements. We currently conduct our operations through two operating
segments: diagnostic services and consumer products. Until late Fiscal 2020, we were engaged primarily in the research, development,
manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. However,
commencing in December 2020, we also began offering COVID-19 and other Respiratory Pathogen Panel (RPP) molecular tests through our new
diagnostic services business, and in August 2021 we began offering personal genomics products and services.
Our
wholly owned subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), which was formed on October 9, 2020, offers
a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain
reaction (“PCR”) testing for COVID-19. Critical to COVID-19 testing, we provide fast turnaround times for results. We also
offer rapid antigen and antibody/immunity testing for COVID-19. On October 23, 2020, we acquired Confucius Plaza Medical Laboratory Corp.
(“CPM”), which included a non-operating but certified 4,000 square foot CLIA accredited laboratory located
in Old Bridge, New Jersey (see Note 3, Business Acquisitions). In December 2020, we expanded our diagnostic service business with the
build out of a second, larger CLIA accredited laboratory in Garden City, New York. Operations at this second facility commenced in January
2021.
On
August 10, 2021, we acquired Nebula Genomics, Inc. (“Nebula”), a privately owned personal genomics company (“Nebula”),
through our new wholly owned subsidiary, ProPhase Precision Medicine, Inc. (“ProPhase Precision”). See Note 3, Business Acquisitions.
ProPhase Precision focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes
and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict
disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.
Our
wholly owned subsidiary, Pharmaloz Manufacturing, Inc. (“PMI”), is a full-service contract manufacturer and private label
developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges and OTC drug and dietary supplement products.
Free historical financial statements for ProPhase Labs Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 51 quarters since 2012. Compare with PRPH stock chart to see long term trends.
Data imported from ProPhase Labs Inc. SEC filings. Check original filings before making any investment decision.